3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
3
Fallopian Tube Neoplasms
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration Resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Colorectal Neoplasms
1
Interventions
Specimen Handling
8
pembrolizumab
7
enfortumab vedotin
7
Magnetic Resonance Spectroscopy
6
avelumab
4
Nivolumab
4
Gemcitabine
3
cabozantinib
2
Ipilimumab
2
Immunoglobulin G
2
Disulfides
2
Cisplatin
2
Carboplatin
2
CTLA-4 Antigen
2
Biopsy
2
vinflunine
1
tremelimumab
1
tocilizumab
1
tamibarotene
1
relatlimab
1
eribulin
1
erdafitinib
1
durvalumab
1
copanlisib
1
atezolizumab
1
Watchful Waiting
1
Standard of Care
1
Propranolol
1
Practice Guidelines as Topic
1
Plasmapheresis
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Ureteral Neoplasms
×
rucaparib
×
1 year
×
Clear all
No trials found.